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creasing age of the population and the im‑
proved survival of cardiovascular patients 
[3]. Stroke is the main complication of AF 
[4]: over 20% of ischemic strokes are linked 
to some form of arrhythmia [1], and in these 
patients, they tend to be more severe than in 
non‑arrhythmic patients [5]. About 40% of 
stroke survivors presents moderate to severe 
disability; applying these rates to the preva‑
lent population, it has been calculated that 
INTRODUCTION
Atrial fibrillation (AF) is the most prevalent 
form of arrhythmia, involving about 1‑2% of 
the population in industrialized countries [1]. 
Its prevalence increases with age, reaching 
values above 5% in the over 65 years old, and 
of 9% in octogenarians [2].
In Italy, a prevalence of 1,000,000 AF pa‑
tients was estimated for year 2010, and a 
further increase is expected due to the in‑
Corresponding author
Lorenzo Pradelli
l.pradelli@adreshe.com
Disclosure
Study funded by 
Bristol‑Myers Squibb 
and Pfizer
ABSTRACT
OBJECTIVES: The study evaluated the cost‑effectiveness of apixaban in preventing thromboembolic events in non‑valvu‑
lar atrial fibrillation (NVAF) patients, as compared to other three available novel oral anticoagulant agents (NOACs), from 
the Italian Health System (SSN) perspective.
METHODS: A previously published lifetime Markov model was adapted for the Italian context. Baseline clinical risks 
were assigned based on the demographic and clinical features of the patients; effectiveness and safety parameters derived 
from adjusted indirect comparison using warfarin as link. The main clinical events considered in the model are ischemic 
and hemorrhagic stroke, systemic thromboembolism, bleeds (both major and clinically relevant minor) and cardiovascular 
hospitalizations, besides treatment discontinuations. Expected survival was projected beyond trial duration using national 
mortality data adjusted for clinical risks and weighted by published utilities. Unit costs were collected from published Ital‑
ian sources and actualized to 2013. Costs and health gains occurring after the first year were discounted at an annual 3.5% 
rate. The primary outcome measure of the economic evaluation was the incremental cost effectiveness ratio (ICER), where 
effectiveness is measured in terms of life‑years and quality adjusted life‑years gained. Deterministic and probabilistic sen‑
sitivity analyses (DSA&PSA) were carried out.
RESULTS: In the short to medium term, apixaban was associated with marginal LYs and QALYs gains and slight savings, 
as compared to other NOACs. However, as apixaban extended expected survival versus dabigatran (110mg), dabigatran 
(150mg) and rivaroxaban (0.13, 0.08, and 0.06 LYs or 0.11, 0.07, and 0.05 QALYs), expected total lifetime costs exceeded 
those of these comparators (€ 319, € 282, and € 16). Corresponding ICERs were estimated in € 2,911, € 3,882 and € 327 per 
QALY gained. The most influential parameter according to DSA was daily costs of NOACs, but the corresponding ICERs 
remained well below commonly accepted WTP values. In PSA, the probabilities of apixaban being cost effective with a 
WTP threshold of 20,000 €/QALY gained were 99%, 92% and 93% for the same comparisons.
CONCLUSIONS: Apixaban is expected to be more effective than dabigatran and rivaroxaban in Italian NVAF popula‑
tion, and marginally more costly due to consume healthcare resources for a longer period of time. The ICERs have a high 
likelihood of being below conventional thresholds of WTP for health benefits of the SSN and suggest that apixaban is 
cost‑effective compared with other three available NOACs. 
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around 384,000 are not autonomous in Italy 
due to stroke, and this figure is expected to 
rise up to 440,000 by 2020 [6].
Therapeutic goals in the management of AF 
patients include symptom control, but also 
the prevention of thromboembolic complica‑
tions, stroke in primis. This was traditionally 
pursued with the administration of vitamin 
K antagonists (VKAs), or with antiplatelet 
agents, mainly aspirin, in subjects intoler‑
ant or contraindicated to VKAs [7]. In the 
last years, however, the class of novel oral 
anticoagulant agents (NOACs) has been in‑
troduced, which is associated with a more 
favorable risk/benefit ratio than VKAs. Until 
recently, dabigatran, a direct thrombin in‑
hibitor, and rivaroxaban, a direct and selec‑
tive coagulation factor Xa inhibitor, were 
the only NOACs licensed for thromboem‑
bolic prevention in non‑valvular AF (NVAF, 
about 70% of all AF cases). Apixaban, also 
a direct and selective coagulation factor Xa 
inhibitor [8], is facing the launch on the mar‑
ket for this indication, with the following re‑
imbursement restrictions: NVAF with both 
CHA2DS2‑VASc ≥ 1
1 and HAS‑BLED > 32, 
or TTR < 70% or objective difficulties in 
measuring INR [9].
Aim of the present analysis is the compara‑
tive economic evaluation of the use of the 
three available NOACs in the prevention of 
thromboembolic events in the Italian popu‑
lation of patients with NVAF with official 
indication for their use, according to current 
regulations.
METHODS
The analysis is conducted with a simulation 
study, performed through the adaptation and 
run of a previously published international 
model [10,11] executed with epidemiologi‑
cal, clinical practice and unit costs pertinent 
to the Italian setting. The model is designed 
to reproduce the experience of a cohort of 
NVAF patients of user defined features, alter‑
natively treated with the available therapeutic 
options: for the present study, dabigatran at 
1 Calculates stroke risk for patients with atrial fibrillation, 
possibly better than the CHADS2 score. It is composed of 
7 domains: age (1 point for ages 65‑74, 2 points for > 74); 
gender (female, 1 point); congestive heart failure history 
(yes, 1 point); hypertension history (yes, 1 point); stroke/TIA/
thromboembolism history (yes, 2 points), vascular disease 
history (yes, 1 point), and diabetes mellitus (yes, 1 point)
2 HAS‑BLED is an acronym for: Hypertension, Abnormal 
Liver/Renal Function, Stroke History, Bleeding Predisposi‑
tion, Labile INR, Elderly (age > 65), Drugs/Alcohol Usage, 
with each of the domains scored 1 point if present, to be 
added up to obtain total score, which correlates with the 
risk of major bleeding. Estimates risk of major bleeding for 
patients on anticoagulation to assess risk‑benefit in atrial 
fibrillation care.
two dose levels (110 mg/bid for the over 80 
years old, 150 mg/bid for younger NVAF pa‑
tients), rivaroxaban (20 mg/uid), and apixa‑
ban (5 mg/bid). During the lifetime simula‑
tion, events and consumed resources from 
the Italian National Health System perspec‑
tive are recorded by the model; main clinical 
outcomes monitored are ischemic and hem‑
orrhagic stroke, systemic thromboembolism, 
bleeds (both major and clinically relevant 
minor), cardiovascular hospitalizations, and 
death. Summary effectiveness indicators 
are overall survival, expressed in life years 
(LYs), and expected quality‑adjusted sur‑
vival, expressed in quality‑adjusted life years 
(QALYs).
Model structure
The model is designed as a decision tree with 
Markov chains as branches; the experience of 
a NVAF patient is discretized in 17 possible 
and mutually exclusive health states (Fig‑
ure 1). Transitions among health states are 
determined by probability matrices derived 
from the relevant literature as detailed else‑
where [11].
At the end of each 6 week cycle, patients can 
stay in the current health state, or experience 
a clinical event and transition to the corre‑
sponding state; some events only imply a re‑
source consumption and a temporary change 
in the utility (quality of life index), whilst oth‑
ers – i.e. stroke, myocardial infarction (MI), 
and systemic embolism – also modify the 
chance of incurring in further events. Stroke 
survivors distribute among subsequent health 
states basing on the assigned severity distri‑
bution of the specific event. Following a ma‑
jor bleeding, patients may continue to receive 
the initial anticoagulant, or switch to a sec‑
ond line treatment, associated with specific 
clinical event risks.
Population
The simulation is run on two cohorts (Table I): 
the first (base‑case) reproducing clinical and 
demographic features of the ARISTOTLE 
trial population [12], the second those of 
a non‑experimental population of NVAF 
patients studied by Olesen et al. [13]. In 
this cohort study, Olesen et al. assessed 
the individual risk factors composing 
the CHADS2 and CHA2DS2‑VASc score 
calculating the capability of the schemes to 
predict thromboembolism in a nationwide 
cohort of Danish real world patients.
Clinical outcomes rates
In general, the model assigns baseline clinical 
risks basing on the demographic and clinical 
features of the patients; these risks evolve ac‑
Figure 1. Simplified structure of the Markov model
Base‑case – ARISTOTLE 
population [12]
Alternative case – 
Real‑world population [13]
% males 65 53
Mean age (years) 70 77
CHADS2 score (%)
0‑1 34 53
2 36 23
> 2 30 24
Table I. Baseline characteristics of the simulated populations: base‑case patient 
populations, from ARISTOTLE trial [12], and alternative‑case population, from a 
nationwide cohort of real‑world patients, registered in the Danish patient registry [13]
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cording to the time elapsed from the begin‑
ning of the simulation, to the risk‑modifying 
clinical events experienced by the patient, 
and to the preventive regimen administered.
The effectiveness and safety profile of 
apixaban reflects event rates recorded in 
the ARISTOTLE trial [12] integrated with 
patient‑level data made available by Dorian 
et al. [10], which showed that apixaban was 
associated with a reduction in the risk of 
stroke or systemic embolism, in bleeding, 
and in all‑cause mortality in AF patients, 
as compared to warfarin. The choice 
of the ARISTOTLE trial, a randomised 
head‑to‑head clinical trial, is related to the 
comparator, warfarin, which is common to 
the pivotal trials in AF of the other NOACs. 
The baseline risk profile can be adjusted 
for different distributions in the simulated 
population vs. the ARISTOTLE population 
of the CHADS2 and the time in therapeutic 
range (TTR), for stroke and bleeding, 
respectively.
Dabigatran was compared to warfarin in AF 
patients in the RELY trial, in which it demon‑
strated similar efficacy in stroke and throm‑
boembolic prevention and lower bleeding 
risk, at the 110 mg bid, and superior stroke 
two dose levels (110 mg/bid for the over 80 
years old, 150 mg/bid for younger NVAF pa‑
tients), rivaroxaban (20 mg/uid), and apixa‑
ban (5 mg/bid). During the lifetime simula‑
tion, events and consumed resources from 
the Italian National Health System perspec‑
tive are recorded by the model; main clinical 
outcomes monitored are ischemic and hem‑
orrhagic stroke, systemic thromboembolism, 
bleeds (both major and clinically relevant 
minor), cardiovascular hospitalizations, and 
death. Summary effectiveness indicators 
are overall survival, expressed in life years 
(LYs), and expected quality‑adjusted sur‑
vival, expressed in quality‑adjusted life years 
(QALYs).
Model structure
The model is designed as a decision tree with 
Markov chains as branches; the experience of 
a NVAF patient is discretized in 17 possible 
and mutually exclusive health states (Fig‑
ure 1). Transitions among health states are 
determined by probability matrices derived 
from the relevant literature as detailed else‑
where [11].
At the end of each 6 week cycle, patients can 
stay in the current health state, or experience 
a clinical event and transition to the corre‑
sponding state; some events only imply a re‑
source consumption and a temporary change 
in the utility (quality of life index), whilst oth‑
ers – i.e. stroke, myocardial infarction (MI), 
and systemic embolism – also modify the 
chance of incurring in further events. Stroke 
survivors distribute among subsequent health 
states basing on the assigned severity distri‑
bution of the specific event. Following a ma‑
jor bleeding, patients may continue to receive 
the initial anticoagulant, or switch to a sec‑
ond line treatment, associated with specific 
clinical event risks.
Population
The simulation is run on two cohorts (Table I): 
the first (base‑case) reproducing clinical and 
demographic features of the ARISTOTLE 
trial population [12], the second those of 
a non‑experimental population of NVAF 
patients studied by Olesen et al. [13]. In 
this cohort study, Olesen et al. assessed 
the individual risk factors composing 
the CHADS2 and CHA2DS2‑VASc score 
calculating the capability of the schemes to 
predict thromboembolism in a nationwide 
cohort of Danish real world patients.
Clinical outcomes rates
In general, the model assigns baseline clinical 
risks basing on the demographic and clinical 
features of the patients; these risks evolve ac‑
Figure 1. Simplified structure of the Markov model
Base‑case – ARISTOTLE 
population [12]
Alternative case – 
Real‑world population [13]
% males 65 53
Mean age (years) 70 77
CHADS2 score (%)
0‑1 34 53
2 36 23
> 2 30 24
Table I. Baseline characteristics of the simulated populations: base‑case patient 
populations, from ARISTOTLE trial [12], and alternative‑case population, from a 
nationwide cohort of real‑world patients, registered in the Danish patient registry [13]
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and embolism prevention, with similar bleed‑
ing risk, at the 150 mg/bid dose [14].
Rivaroxaban was compared to warfarin in the 
ROCKET‑AF trial, demonstrating non inferi‑
ority in the prevention of stroke and throm‑
boembolism in NVAF patients, and similar 
bleeding risk [15].
Data from the VKA‑suitable population of 
these trials (ARISTOTLE, RELY, and ROCK‑
ET‑AF) were included in indirect treatment 
comparisons [11], using warfarin as common 
comparator, to obtain relative risks or hazard 
ratios of each of the NOACs vs. apixaban, for 
each evaluated outcome (Table II).
For apixaban, the risk of incurring an isch‑
emic stroke (IS) is directly extrapolated from 
ARISTOTLE in the base case analysis, and 
adjusted for the CHADS2 distribution in Ole‑
sen et al. for the alternative scenario; for the 
competing NOACs, the rate is calculated by 
applying the relevant HR to the apixaban haz‑
ard in both analyses. Increasing age is associ‑
ated with higher IS risk; in the model, this is 
accounted for by applying a HR of 1.4 per de‑
cade [16]. Severity distribution of IS is clas‑
sified according to the modified Rankin scale 
(mRS ‑ mild 0‑2; moderate 3‑4; severe 5 and 
fatal 6) specific to the AC treatment and was 
derived from published literature (Table II).
As with IS, in the base‑case analysis the ab‑
solute intracranial hemorrhage (ICH) hazard 
rate for apixaban is directly obtained from 
ARISTOTLE; specific HRs are applied to 
these rates to determine the hazard rates for 
dabigatran and rivaroxaban. The model ac‑
counts for age‑related increase in ICH risk by 
applying a 1.97 HR per decade [17]. Hemor‑
rhagic strokes (HS) are determined as a treat‑
ment‑specific percentage of ICHs; similarly, 
their severity distribution, again expressed in 
terms of mRS, is treatment‑specific.
IS and HS survivors are at risk of recurrence: 
this is modeled according to a real‑life regis‑
try indicating a cumulative incidence of 4.1 
and 3.0 per 100 patient‑years, respectively 
[18]; the severity distribution of recurrent 
strokes for all alternatives is conditional on 
the severity of the first stroke, as observed in 
ARISTOTLE and AVERROES [19].
As with IS and ICH, the model accounts for 
increasing MI risk with advancing age of the 
cohort by applying an HR of 1.30 per decade 
[20]. MI case fatality rates applied in the sim‑
Apixaban  
[10,11]
Dabigatran 
(110 mg) [11]
Dabigatran 
(150 mg) [11]
Rivaroxaban [11]
Aspirin (2nd line) 
[10,11]
IS*
Rate/100 pts‑yr 0.98 3.456
HR (95% CI) vs. apixaban 1.20 (0.88‑1.64) 0.82 (0.59‑1.14) 0.98 (0.72‑1.33)
Pts distribution (%)
 • Mild mRS (0‑2) 53 35 35 49 365
 • Moderate mRS (3‑4) 21 28 22 18 385
 • Severe mRS (5) 8 10 8 6 155
 • Fatal mRS (6) 18 27 35 27 115
ICH*
Rate/100 pts‑yr 0.33 0.326
HR (95% CI) vs. apixaban 0.73 (0.43‑1.26) 1.02 (0.62‑1.68) 1.73 (1.08‑2.77)
Other ICH (%) 23 36 59 43 455
Case Fatality Rates (%) 133 132 132 132 135
Proportion of HS (%) 77 64 41 57 555
 • Mild mRS (0‑2) 23 35 35 49 75
 • Moderate mRS (3‑4) 32 28 22 18 205
 • Severe mRS (5) 10 10 8 6 275
 • Fatal mRS (6) 35 27 35 27 465
Other MB*
Rate/100 pts‑yr 1.79 0.896
HR (95% CI) vs. apixaban 1.21 (0.97‑1.50) 1.37 (1.10‑1.70) 1.44 (1.15‑1.79)
Case Fatality Rates 23 22 22 22 25
Proportion of GI Bleeds 38 41 49 45 395
CRNM*
Rate/100 pts‑yr 2.08 2.946
HR (95% CI) vs. apixaban 1.16 (0.99‑1.35) 1.30 (1.11‑1.53) 1.49 (1.26‑1.76)
MI*
Rate/100 pts‑yr 0.53 1.116
HR (95% CI) vs. apixaban 1.474 (0.96‑2.27) 1.46 (0.95‑2.24) 0.94 (0.64‑1.38)
SE
Rate/100 pts‑yr 0.09 0.404
HR (95% CI) vs. apixaban 12 12 12
Other CV Hosp
Rate/100 pts‑yr 10.461 13.576
HR (95% CI) vs. apixaban 12 12 12
Other Treat Disc
Rate/100 pts‑yr 13.18 ‑
HR (95% CI) vs. apixaban 1.45 (1.31‑1.61) 1.51 (1.36‑1.67) 1.18 (1.08‑1.29)
Background mortality°
Rate/100 pts‑yr 3.08 ‑
HR (95% CI) vs. apixaban 12 12 12
Table II. Summary of main clinical inputs used in the analysis
CRNM: Clinically Relevant non Major Bleeds; GI: Gastro‑Intestinal Bleeds; HS: Hemorrhagic Stroke; ICH: IntraCranial Hemorrhages; IS: Ischemic 
Stroke; MI: Myocardial Infarction; Other CV Hosp: Other Cardio‑Vascular Hospitalization; Other MB: other Major Bleeds; Other TreatDisc: Other 
Treatment Discontinuation; pts: patients; SE: Systemic Embolism; yr: year
1 Assume same rate as the apixaban’s rate observed among the VKA unsuitable population
2 Assume same risk as apixaban
3 Pooled sample percentages
4 Assume same rate as ASA first line observed in the VKA unsuitable population
5 Assume same distribution as ASA first line
6 Subgroup of patients who had VKA‑unsuitability “demonstrated” (i.e., previously failed warfarin)
* Stroke, bleeds and MI risks are adjusted over time to take into account the increased risks with aging: HR for adjunctive decade of 1.4 [16], 1.97 
[17], and 1.3 [20], respectively, are applied
° For the duration of the trial follow‑up
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ulation are specific for gender (10.8% in men 
and 15.6 for women), differently than for SE 
(9.4%) [21].
During the simulation, patients may dis‑
continue treatment, either completely, or by 
switching to another AC regimen, as a con‑
sequence of clinical events incurred, or for 
other reasons as described in Lip et al. [11].
Besides the already described case fatality 
rates for stroke, bleeding, and MI, the popula‑
tion is subjected to a background mortality de‑
rived from ARISTOTLE for the duration of the 
trial follow‑up; given the lack of sound com‑
parative mortality rates, the same background 
mortality has been applied to all NOACs.
Beyond the trial duration, mortality is pro‑
jected based on Gompertz distributions fitted 
on Italian age‑ and gender specific population 
rates [22], corrected for the HRs associated to 
AF, MI, stroke, and SE, as shown in Table III.
Utility
Baseline utility assigned to the simulated 
population derives from a preference study 
Health 
condition
NVAF [23]
Stroke [24‑26] MI [27]
SE*
Mild Moderate Severe Female Male
HR 1.34 3.18 5.84 15.75 4.16 2.56 1.34
Table III. Death hazard ratios according to the health condition of the simulated patient
* Assumption
Condition
Mean utility 
[28]
Disutility  
(duration)
Atrial fibrillation (Baseline) 0.7270
Ischemic stroke
Mild 0.6151
Moderate 0.5646
Severe 0.5142
Hemorrhagic stroke
Mild 0.6151
Moderate 0.5646
Severe 0.5142
Myocardial infarction 0.6098
Systemic embolism 0.6265
Other intracranial 
hemorrhages
‑0.1511 [28] (6 weeks [10,11])
Other major bleeding ‑0.1511 [28] (14 days)*
Clinical relevant,  
non major bleeds
‑0.0582 [28] (2 days)*
Other CV hospitalizations ‑0.1276 [28] (6 days [10,11])
Drug utilization
Aspirin ‑0.0020 [29]
Warfarin ‑0.0120 [29]
Table IV. Utilities and disutilities used in the simulation
* Assumption based on Freeman, 2011 [18] and reported on Dorian, 2014 [10] and Lip, 
2014 [11]
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ing risk, at the 150 mg/bid dose [14].
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 ‑ Other health care costs associated with 
AC management (Table VI).
Stroke management costs have been elabo‑
rated based on data reported in an observa‑
tional study conducted on 411 Italian stroke 
survivors, followed up for 12 months [32]: 
for each severity category within ischemic 
and hemorrhagic strokes, the mean long‑term 
maintenance cost has been approximated 
to the monthly cost recorded in the second 
semester; the costs for the acute phase cor‑
respond to the sum of the corresponding 
DRG tariff [33] and the difference between 
the costs accrued in the first and second fol‑
low‑up semester.
For acute and long‑term MI management, 
cost data are elaborated basing on three‑year 
follow‑up data reported for Italian MI sur‑
vivors [34]. The costs attributed to the other 
clinical events considered are equaled to the 
corresponding DRG‑based tariff [33] paid to 
the hospitals by the SSN.
Other AC related costs considered are relat‑
ed to dyspepsia management (€ 71.46/year 
[35], rates of dyspepsia from ARISTOTLE 
for apixaban and warfarin, from adjusted 
indirect comparison for dabigatran, and as‑
sumed equal to apixaban for rivaroxaban) 
and to renal function monitoring for dabiga‑
tran treated patients at risk (19.4%, according 
to RELY data), equaled to the corresponding 
tariff of € 8.16 [33].
All historical cost data have been actualized 
to 2013 values using official indices [22].
Incremental cost/effectiveness
Lifetime results from the simulation are pre‑
sented as incremental cost/effectiveness and 
incremental cost/utility ratios, i.e. as the ratio 
Drug Daily dose (mg/die) Daily cost (€)
Aspirin 100 0.04
Apixaban 10 1.90
Dabigatran (110 mg) 220 1.90
Dabigatran (150 mg) 300 1.90
Rivaroxaban 20 1.80
Table V. Drug acquisition costs, at negotiated net prices [30]
Unit cost (€) Unit Duration Source
Routine visit 15.37 per visit N/A Lucioni et al. [31]
Ischemic Stroke
Mild
 • Acute 4,663.06 per episode 2 weeks Fattore et al. [32]
 • Maintenance 81.76 per month Lifetime Fattore et al. [32]
Moderate
 • Acute 6,137.96 per episode 2 weeks Fattore et al. [32]
 • Maintenance 139.04 per month Lifetime Fattore et al. [32]
Severe
 • Acute 10,311.34 per episode 2 weeks Fattore et al. [32]
 • Maintenance 327.95 per month Lifetime Fattore et al. [32]
Fatal 3,891.00 per episode N/A DRG 14 [33]
Hemorrhagic stroke
Mild
 • Acute 6,321.14 per episode 2 weeks Fattore et al. [32]
 • Maintenance 118.11 per month Lifetime Fattore et al. [32]
Moderate
 • Acute 10,073.43 per episode 2 weeks Fattore et al. [32]
 • Maintenance 200.86 per month Lifetime Fattore et al. [32]
Severe
 • Acute 20,932.42 per episode 2 weeks Fattore et al. [32]
 • Maintenance 473.77 per month Lifetime Fattore et al. [32]
Fatal 3,891 per episode N/A DRG 14 [33]
Other ICH 25,812 per episode N/A DRG 528 [33]
Other major bleeding 3,317 per episode N/A DRG 174 [33]
CRNMB 2,091 per episode N/A DRG 175 [33]
IM
 • Acute 6,275.21 per episode N/A Mantovani et al. [34]
 • Maintenance 157.97 per month Lifetime Mantovani et al. [34]
SE
 • Acute 4,663.06 per episode 2 weeks Assumption
 • Maintenance 81.76 per month Lifetime Assumption
Other CV hospitalization 4,742 per episode N/A DRG 479 [33]
Table VI. Cost inputs
to patients experiencing clinical events, as 
shown in Table IV.
Costs
The analyses are performed taking the per‑
spective of the National Health System 
(SSN); accordingly, only direct health care 
costs are considered:
 ‑ Drug acquisition costs, at negotiated net 
prices [30] (Table V);
 ‑ Routine visits [31] for all treated patients;
 ‑ Acute event management (strokes, 
bleeds, myocardial infarction, and other 
CV hospitalizations);
 ‑ Long‑term post‑event management for 
stroke, MI, and SE;
conducted on AF patients [28]. The model 
accounts for reduced preference for ASA 
administration, as reported in Gage et al. 
1996 [29]; temporary disutilities are assigned 
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of the difference in costs over the difference 
in life years and quality‑adjusted life years, 
respectively.
The effect of parameter uncertainty on the 
results is assessed by probabilistic sensitiv‑
ity analyses (PSA), in which the model is 
re‑evaluated with 2000 sets of parameter val‑
ues sampled from appropriate distributions. 
The influence of single parameters on the 
results is evaluated with a series of one‑way 
deterministic sensitivity analyses (DSA), in 
which the model is re‑calculated using ex‑
treme parameter values, corresponding to the 
lower and upper limits of the 95% confidence 
interval; when this was unavailable from the 
original data, it has been calculated assuming 
a SEM equaling 25% of the mean.
Costs and benefits accruing after the first year 
are discounted at a 3.5% annual rate.
RESULTS
In Table VII, main results of the simulation 
for all alternatives at 1,2, and 3 years. Look‑
ing at the evolution of total costs associated 
to the use of the available NOACs, it can be 
seen that apixaban results less expensive than 
the comparators in the first years. Neverthe‑
less, from Table VIII where lifetime ICER 
results are presented, it can be seen that to‑
tal lifetime costs associated with apixaban 
treatment are expected to exceed those of the 
comparators. This can be easily explained 
with a well‑known paradox in health eco‑
nomic analyses: life‑extending therapies in‑
crease cost, simply because they prolong the 
survival of patients that continue to consume 
healthcare resources for a longer period of 
time.
Year 1 Year 2 Year 3
Total cost (€) QALY LY Total cost (€) QALY LY Total cost (€) QALY LY
Apixaban 1,425 0.65 0.90 2,961 1.36 1.88 4,436 2.04 2.83
Dabigatran (110 mg) 1,449 0.65 0.90 2,992 1.36 1.88 4,461 2.04 2.82
Dabigatran (150 mg) 1,459 0.65 0.90 3,007 1.36 1.88 4,476 2.04 2.82
Rivaroxaban 1,459 0.65 0.90 3,020 1.36 1.88 4,511 2.04 2.82
Table VII. Base‑case – main simulation results
Total cost 
(€)
Incremental 
cost (€)
LY
Incremental 
LY
Cost per LY 
gained (€)
QALY
Incremental 
QALY
Cost per QALY 
gained (€)
Apixaban 14,028 9.12 6.48
Dabigatran (110mg) 13,709 319 8.99 0.13 2,496 6.37 0.11 2,911
Dabigatran (150mg) 13,746 282 9.04 0.08 3,318 6.41 0.07 3,882
Rivaroxaban 14,012 16 9.06 0.06 262 6.43 0.05 327
Table VIII. Base‑case CEA results (results are presented as apixaban vs. comparator)
 ‑ Other health care costs associated with 
AC management (Table VI).
Stroke management costs have been elabo‑
rated based on data reported in an observa‑
tional study conducted on 411 Italian stroke 
survivors, followed up for 12 months [32]: 
for each severity category within ischemic 
and hemorrhagic strokes, the mean long‑term 
maintenance cost has been approximated 
to the monthly cost recorded in the second 
semester; the costs for the acute phase cor‑
respond to the sum of the corresponding 
DRG tariff [33] and the difference between 
the costs accrued in the first and second fol‑
low‑up semester.
For acute and long‑term MI management, 
cost data are elaborated basing on three‑year 
follow‑up data reported for Italian MI sur‑
vivors [34]. The costs attributed to the other 
clinical events considered are equaled to the 
corresponding DRG‑based tariff [33] paid to 
the hospitals by the SSN.
Other AC related costs considered are relat‑
ed to dyspepsia management (€ 71.46/year 
[35], rates of dyspepsia from ARISTOTLE 
for apixaban and warfarin, from adjusted 
indirect comparison for dabigatran, and as‑
sumed equal to apixaban for rivaroxaban) 
and to renal function monitoring for dabiga‑
tran treated patients at risk (19.4%, according 
to RELY data), equaled to the corresponding 
tariff of € 8.16 [33].
All historical cost data have been actualized 
to 2013 values using official indices [22].
Incremental cost/effectiveness
Lifetime results from the simulation are pre‑
sented as incremental cost/effectiveness and 
incremental cost/utility ratios, i.e. as the ratio 
Drug Daily dose (mg/die) Daily cost (€)
Aspirin 100 0.04
Apixaban 10 1.90
Dabigatran (110 mg) 220 1.90
Dabigatran (150 mg) 300 1.90
Rivaroxaban 20 1.80
Table V. Drug acquisition costs, at negotiated net prices [30]
Unit cost (€) Unit Duration Source
Routine visit 15.37 per visit N/A Lucioni et al. [31]
Ischemic Stroke
Mild
 • Acute 4,663.06 per episode 2 weeks Fattore et al. [32]
 • Maintenance 81.76 per month Lifetime Fattore et al. [32]
Moderate
 • Acute 6,137.96 per episode 2 weeks Fattore et al. [32]
 • Maintenance 139.04 per month Lifetime Fattore et al. [32]
Severe
 • Acute 10,311.34 per episode 2 weeks Fattore et al. [32]
 • Maintenance 327.95 per month Lifetime Fattore et al. [32]
Fatal 3,891.00 per episode N/A DRG 14 [33]
Hemorrhagic stroke
Mild
 • Acute 6,321.14 per episode 2 weeks Fattore et al. [32]
 • Maintenance 118.11 per month Lifetime Fattore et al. [32]
Moderate
 • Acute 10,073.43 per episode 2 weeks Fattore et al. [32]
 • Maintenance 200.86 per month Lifetime Fattore et al. [32]
Severe
 • Acute 20,932.42 per episode 2 weeks Fattore et al. [32]
 • Maintenance 473.77 per month Lifetime Fattore et al. [32]
Fatal 3,891 per episode N/A DRG 14 [33]
Other ICH 25,812 per episode N/A DRG 528 [33]
Other major bleeding 3,317 per episode N/A DRG 174 [33]
CRNMB 2,091 per episode N/A DRG 175 [33]
IM
 • Acute 6,275.21 per episode N/A Mantovani et al. [34]
 • Maintenance 157.97 per month Lifetime Mantovani et al. [34]
SE
 • Acute 4,663.06 per episode 2 weeks Assumption
 • Maintenance 81.76 per month Lifetime Assumption
Other CV hospitalization 4,742 per episode N/A DRG 479 [33]
Table VI. Cost inputs
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Figure 2. Tornado chart illustrating results from DSA for the ICER (€/QALY gained) of apixaban vs. dabigatran 110 mg/bid. 
The extreme values tested for each parameter are reported on the same line of the corresponding – results in parenthesis indicate 
negative ICERs, i.e., dominance of apixaban
Figure 3. Tornado chart illustrating results from DSA for the ICER (€/QALY gained) of apixaban vs. dabigatran 150 mg/bid. 
The extreme values tested for each parameter are reported on the same line of the corresponding – results in parenthesis indicate 
negative ICERs, i.e., dominance of apixaban
Figure 4. Tornado chart illustrating results from DSA for the ICER (€/QALY gained) of apixaban vs. rivaroxaban. The extreme values 
tested for each parameter are reported on the same line of the corresponding – results in parenthesis indicate negative ICERs, i.e., 
dominance of apixaban
Figure 5. PSA: scatterplots of ICERs of apixaban vs. dabigatran 110 mg/bid (panel A), dabigatran 150 mg/bid (panel B), and rivaroxaban 
(panel C). The two lines represent WTP thresholds: 20,000 and 30,000 €/QALY gained (lower and upper, respectively). The diamond 
indicate the base case ICER
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cost‑effective in the head‑to‑head compari‑
son with dabigatran 110 mg, for the conven‑
tional WTP thresholds of 20,000 and 30,000 
€/QALY gained, respectively. Corresponding 
percentages for the comparison with dabi‑
gatran 150 mg and rivaroxaban are 92% and 
94%, and 93% and 94%, for the same con‑
ventional WTP thresholds, respectively.
Main results of the simulation run on a 
non‑experimental population of NVAF pa‑
tients [13] for all alternatives at 1,2, and 3 
years, as well as in a lifetime horizon, are 
presented in Table IX.
Alternative scenario results (Table X) are 
even more favorable for apixaban: when 
compared with dabigatran (both 110 mg and 
150 mg), the estimated ICERs are around 
3,000 €/QALY gained ; in the comparison 
with rivaroxaban, apixaban is expected to 
dominate, being associated to lower costs 
and better effectiveness.
CONCLUSIONS
The expected economic differences among 
NOACs stem from the different safety and 
Figure 6. Probability of being the most cost‑effectiveness treatment choice
Year 1 Year 2 Year 3 Lifetime
Total 
cost (€)
QALY LY
Total 
cost (€)
QALY LY
Total 
cost (€)
QALY LY
Total 
cost (€)
QALY LY
Apixaban 1,419 0.65 0.90 2,942 1.36 1.88 4,366 2.02 2.80 10,861 5.10 7.12
Dabigatran (110 mg) 1,441 0.65 0.90 2,971 1.36 1.88 4,385 2.02 2.79 10,624 5.02 7.02
Dabigatran (150 mg) 1,454 0.65 0.90 2,992 1.36 1.88 4,413 2.02 2.79 10,687 5.04 7.05
Rivaroxaban 1,453 0.65 0.90 3,004 1.36 1.88 4,445 2.02 2.80 10,896 5.06 7.07
Table IX. Alternative population – main simulation results
Comparator
Incremental cost 
(€)
Incremental 
QALY
Cost per QALY 
gained (€)
Incremental LY
Cost per LY 
gained (€)
Dabigatran (110 mg) 237 0.08 2,971 0.10 2,470
Dabigatran (150 mg) 174 0.05 3,230 0.06 2,706
Rivaroxaban ‑35 0.03 Dominant 0.04 Dominant
Table X. Lifetime CEA results on a non‑experimental cohort [13] – results are presented as apixaban vs. comparator
Incremental cost/effectiveness and cost/
utility ratios are calculated taking apixaban 
as reference, consistently with its expected 
best effectiveness profile, and are presented 
in Table VIII. The ICERs calculated for the 
comparison with the other alternatives indi‑
cate a favorable pharmacoeconomic profile, 
being quite lower than any usual threshold of 
the willingness to pay for health benefits of 
the SSN, or of any other third party payer in 
industrialized countries.
DSA for the analyses are represented as tor‑
nado diagrams in Figure 2, Figure 3, and 
Figure 4, showing the impact of single pa‑
rameters on the estimated ICERs in order 
of decreasing magnitude of effect. The most 
influential parameters are the daily costs of 
the compared molecules, but the correspond‑
ing ICERs remain well below commonly ac‑
cepted WTP values.
Probabilistic sensitivity analysis also sub‑
stantially confirms the findings of the main 
analysis, as shown in Figure 5, representing 
the distribution of the 2000 ICER estimates 
of the PSA.
PSA results are also displayed as cost/effec‑
tiveness acceptability curves (Figure 6), in 
which the estimated probability of being the 
most cost/effective treatment is shown for ev‑
ery regimen at increasing willingness to pay 
(WTP) thresholds: apixaban is expected to 
be the best choice for any WTP above about 
5,000 €/QALY gained. Apixaban has 99% 
and 100% expected probabilities of being 
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effectiveness profile of the NOACs emerging 
from the adjusted indirect comparison.
Dabigatran, at the 110 mg BID dose, appears 
associated with a lower ICH risk than apix‑
aban, but this should be traded off with an 
apparent inferior protection against ischemic 
strokes; the latter can be mitigated with the 
higher dabigatran dose (150 mg BID) or with 
the use of rivaroxaban, but at the expense of 
much higher bleeding risks. However, from 
an economical point of view, neither trade‑off 
is expected to be efficient.
In conclusion, analyses using the demonstrat‑
ed relative effectiveness and safety profiles 
indicate that the different balance between 
ischemic protection and increased bleeding 
risk is more favourable from a health eco‑
nomics perspective with apixaban than with 
the other NOACs: the pharmacoeconomic 
analyses performed and the findings present‑
ed in this paper clearly support the economic 
value of apixaban in Italian NVAF patients. 
Since cost effectiveness results appeared to 
be even more prominent when the model was 
simulated using real world data, it appears 
that our base‑case may be conservative.
cost‑effective in the head‑to‑head compari‑
son with dabigatran 110 mg, for the conven‑
tional WTP thresholds of 20,000 and 30,000 
€/QALY gained, respectively. Corresponding 
percentages for the comparison with dabi‑
gatran 150 mg and rivaroxaban are 92% and 
94%, and 93% and 94%, for the same con‑
ventional WTP thresholds, respectively.
Main results of the simulation run on a 
non‑experimental population of NVAF pa‑
tients [13] for all alternatives at 1,2, and 3 
years, as well as in a lifetime horizon, are 
presented in Table IX.
Alternative scenario results (Table X) are 
even more favorable for apixaban: when 
compared with dabigatran (both 110 mg and 
150 mg), the estimated ICERs are around 
3,000 €/QALY gained ; in the comparison 
with rivaroxaban, apixaban is expected to 
dominate, being associated to lower costs 
and better effectiveness.
CONCLUSIONS
The expected economic differences among 
NOACs stem from the different safety and 
Figure 6. Probability of being the most cost‑effectiveness treatment choice
Year 1 Year 2 Year 3 Lifetime
Total 
cost (€)
QALY LY
Total 
cost (€)
QALY LY
Total 
cost (€)
QALY LY
Total 
cost (€)
QALY LY
Apixaban 1,419 0.65 0.90 2,942 1.36 1.88 4,366 2.02 2.80 10,861 5.10 7.12
Dabigatran (110 mg) 1,441 0.65 0.90 2,971 1.36 1.88 4,385 2.02 2.79 10,624 5.02 7.02
Dabigatran (150 mg) 1,454 0.65 0.90 2,992 1.36 1.88 4,413 2.02 2.79 10,687 5.04 7.05
Rivaroxaban 1,453 0.65 0.90 3,004 1.36 1.88 4,445 2.02 2.80 10,896 5.06 7.07
Table IX. Alternative population – main simulation results
Comparator
Incremental cost 
(€)
Incremental 
QALY
Cost per QALY 
gained (€)
Incremental LY
Cost per LY 
gained (€)
Dabigatran (110 mg) 237 0.08 2,971 0.10 2,470
Dabigatran (150 mg) 174 0.05 3,230 0.06 2,706
Rivaroxaban ‑35 0.03 Dominant 0.04 Dominant
Table X. Lifetime CEA results on a non‑experimental cohort [13] – results are presented as apixaban vs. comparator
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